These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11384101)

  • 21. Identification of early p53 mutations in clam ileocystoplasties using restriction site mutation assay.
    Ivil KD; Jenkins SA; Doak SH; Hawizy AM; Kynaston HG; Parry EM; Jenkins GJ; Parry JM; Stephenson TP
    Urology; 2007 Nov; 70(5):905-9. PubMed ID: 17919692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
    Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
    Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A highly sensitive detection method for somatic mutations in p53 gene.
    Sato T; Sato A; Ishihara H; Konishi K
    Rinsho Byori; 2003 Feb; 51(2):98-106. PubMed ID: 12690626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method.
    Masuda A; Kikuchi YY; Kawamura N
    Tokai J Exp Clin Med; 2000 Jun; 25(2):69-77. PubMed ID: 11127510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer.
    Gallo O; Chiarelli I; Bianchi S; Calzolari A; Simonetti L; Porfirio B
    Clin Cancer Res; 1996 Sep; 2(9):1577-82. PubMed ID: 9816336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.
    Lee SH; Shin MS; Park WS; Kim SY; Dong SM; Pi JH; Lee HK; Kim HS; Jang JJ; Kim CS; Kim SH; Lee JY; Yoo NJ
    Cancer Res; 1999 Jul; 59(13):3068-72. PubMed ID: 10397246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
    Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
    Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.
    Moonen PM; van Balken-Ory B; Kiemeney LA; Schalken JA; Witjes JA
    J Urol; 2007 Jan; 177(1):80-3. PubMed ID: 17162008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
    Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
    Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer.
    Besaratinia A; Bates SE; Pfeifer GP
    Cancer Res; 2002 Aug; 62(15):4331-8. PubMed ID: 12154037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
    Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
    J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene.
    Yamada K; Zhong X; Kanazawa S; Koike J; Tsujita K; Hemmi H
    Oncol Rep; 2003; 10(4):859-66. PubMed ID: 12792735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
    Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
    Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.